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Evaluation of forskolin 
as an agonist of ULK1, 




Introduction and Background 
 Autophagy is a necessary cellular 
process in which old or malfunctioning 
components of the cell are degraded and 
recycled into their base components. This 
process is necessary, and the malfunction of 
autophagy can result in the build-up of 
poorly functioning organelles, the 
prevention of necessary cell death to 
improve overall tissue efficiency, and harm 
to the cell’s overall metabolic state. It is the 
focus of this project to investigate the 
workings of autophagy in hepatic cells in 
both in vitro models, as well as in vivo as 
tested in a mouse model. Two depictions of 




Figure 1: Base depiction of autophagy 
process. (SelfHacked, 2018) 
 
 
Figure 2: Protein interaction depiction of 
autophagy process. (InvivoGen, 2017) 
  
ULK1 is one of the major proteins 
involved in the formation of the 
autophagosome, and the formation of the 
autophagosome is a critical step in the 
induction of autophagy. Thus, it was 
determined that identifying an agonist of 
ULK1 could be used as a proxy for 
potentially modulating autophagy 
expression. As such, two distinct questions 
were being asked with this project; whether 
an agonist for ULK1 could be identified, and 
if this agonist would then also act as a 
general agonist for autophagy. 
For the purposes of this project, the 
identification of a ULK1 agonist was limited 
to hepatic cells. Thus, the results of this 
project are limited in scope to their effects in 
hepatic cells, as other cell types are likely to 
exhibit different metabolic conditions that 
may interact differently with any identified 
ULK1 agonist. As such, more investigation 
should be completed if the results of this 
project are to be extrapolated to other cell 
lines. In addition, due to the requirements to 
identify a ULK1 agonist and the number of 
experimental lines of investigation needed to 
confirm the function as a general autophagy 
agonist, this project is limited to the analysis 
of forskolin as both a ULK1 agonist and the 
characterization of its effects on autophagy. 
This factor had already been identified by 
Dr. Young Do Koo prior to the initiation of 
this project, due to background research into 
forskolin’s purported agonistic activity to 
autophagy. 
 There is limited research into 
potential agonists of autophagy, and for 
which cell types these agonists are valid for. 
Basic research into the role of forskolin in 
autophagy suggests that it operates through 
the activation of protein kinase A (PKA), 
which in turn regulates cellular processes 
involved in stress response, metabolism, and 
survival processes, such as autophagy 
(Chiaradonna, Pirola, Ricciardiello, & 
Palorini, 2016). However, this research is 
limited to the fibroblast cell type, and as 
such does not control for accessory factors 
that forskolin may also activate. 
Furthermore, it has been shown that 
adenylyl cyclase has a critical role in the 
induction of autophagy. (Chen, et al., 2013) 
Research into the metabolic pathway of 
autophagy has shown that forskolin acts as 
an activator of adenylyl cyclase, (Zhang, 
Zeng, Shen, Tian, & Yang, 2018) which 
may in turn result in the overall induction of 
autophagy. Given these correlations between 
forskolin and autophagy induction, it was 
determined to first investigate forskolin’s 
role in autophagy prior to the screening of 
any additional drugs.  
ULK1 levels were monitored as a 
proxy to autophagy modulation, and it was 
assumed that changes in the expression 
levels of ULK1 would cause downstream 
effects on autophagy due to the ease of 
formation of the autophagosome. Given that 
forskolin may have additional effects on 
accessory factors related to and modulated 
by the activation of autophagy, it was 
determined that these factors would also be 
monitored to ensure that accessory effects 
caused by the addition of forskolin were 
controlled for. In this manner, forskolin was 
screened as only a ULK1 agonist, while 
limiting any accessory effects. In addition, it 
was this concern over accessory effects that 
necessitated an extended screening of 
forskolin. Given the differences in metabolic 
processes in different cell types, it was 
unclear what exact effects forskolin would 
have in hepatic cell lines, and if these effects 
would even resemble those documented in 
previous research.  
There are multiple metabolic 
controllers of autophagy, and while the 
entirety of the process is not fully 
understood, there is large support that ULK1 
and ULK2, which are proteins found within 
the cell, modulate the formation of the 
autophagosome. The autophagosome is the 
structure that enables the autophagy process, 
as it forms to degrade and recycle the 
components present inside of it. As such, 
research performed in this project as well as 
in the overarching research scheme focused 
on understanding autophagy using ULK1 
and ULK2 as factors to modulate the 
occurrence of autophagy. The importance of 
ULK1 can be visualized in figure 1, and the 
importance of ULK2 associated with ULK1 
can be visualized in figure 2. Finally, an 
overview of autophagosome formation can 
be visualized on figure 3. To initiate 
autophagy induction and autophagosome 
formation, ULK1, ULK2, Atg13, FIP200 all 
complex together to initiate autophagosome 
formation, among other factors. It was this 
complex formation that initially led to the 
investigation of the roles of ULK1 and 





Figure 1: Depiction of the importance of 
ULK1 in triggering autophagy induction. 
 
Figure 2: Depiction of the association 
between ULK1 and ULK2 in autophagy 
induction 
 
Figure 3: Depiction of the overall formation 
of the autophagosome, with contributing 
metabolic factors. 
 Given that the formation of the 
autophagosome utilizes a variety of ancillary 
metabolic factors and proteins, a selection of 
these factors was used to identify the effects 
of a ULK1 agonist towards autophagy. 
These selected factors included ATG13, 
GAPDH, FIP200, LC3B, p62, Bnip3, AKT, 
and Beclin1, along with the expression 
levels of ULK1. In this manner, the overall 
effect of a ULK1 agonist could be identified, 
and any accessory effects other than the 
increase of ULK1 transcription could be 
identified. These accessory effects 
represented the largest concern for this 
project, as the agonist’s primary effect 
should be to increase the activation of ULK1 
to avoid changing the other experimental 
conditions of the overarching experiment. 
The levels of these metabolic factors were 
both identified using western blot analysis as 
well as through analysis of transcription 
levels through RNA analysis. 
 The main marker used in this 
experiment was the expression level of 
ULK1, as while it is known that ULK1 plays 
a major role in the formation of the 
autophagosome, the specific metabolic 
processes surrounding ULK1’s involvement 
are being investigated. FIP200 was utilized 
as a marker of autophagy, as it has a known 
role in autophagy induction and complex 
formation with ULK1. (Liu, et al., 2013) In 
addition, ATG13 is also known to have a 
role in this complex and was utilized as a 
marker accordingly (Wei, Wang, Croce, & 
Guan, 2014). Next, p62 was identified as an 
important autophagy marker, as it has a 
defined role in the recognition of toxic waste 
needing removal through autophagy (Lippai 
& Low, 2014). As such, when a cell is 
autophagy-deficient, p62 begins to build up 
in the cell and can be measured as a marker 
of autophagy-deficiency. With the given 
goal for an autophagy activator, the 
expectation would be for p62 levels to 
decrease in autophagy-agonist treatment 
conditions, or at the very least remain 
constant. Beclin1 was identified as a marker 
of interest due to its known role in the 
induction of autophagy. Specifically, 
Beclin1 has defined roles in autophagosome 
nucleation and maturation (Kang, Zeh, 
Lotze, & Tang, 2011). LC3 (monitored as 
LC3B) was also noted as a reliable marker 
of autophagy, as it commonly reflects 
starvation-induced autophagy activity 
(Tanida, Ueno, & Kominami, 2008). 
GAPDH was utilized as a marker of 
autophagy induction due to starvation, as 
literature indicates that GAPDH 
phosphorylation by AMPK—due to glucose 
starvation—increases Sirt1 activation and 
autophagy induction (Chang, et al., 2015). 
Bnip3 was also utilized as a key marker of 
autophagy, as Bnip3 acts as a potent inducer 
of autophagy in many cell types (Quinsay, 
Thomas, Lee, & Gustafsson, 2010). 
 In monitoring the effects of the 
proposed ULK 1 agonist, along with the 
effects of insulin addition, a new set of 
factors were utilized to characterize the 
effect on autophagy. Consistent with 
previous experimental conditions, ULK1 
was maintained as the main marker of 
autophagy induction. Given that the desired 
effect was to increase the expression of 
ULK1, this factor needed to show increased 
levels in all experimental trials treated with 
forskolin. The next factor that was utilized 
was AKT, both in its non-phosphorylated 
and its phosphorylated forms. AKT has 
established roles in the inhibition of 
autophagy through the modulation of 
Beclin1, and as such its use as a marker 
indirectly analyzed the hypothesized 
agonist’s effect on autophagy (Wang, et al., 
2012).  
 In the overarching research scheme, 
both cell models and mouse models were 
developed into three breeds to display 
significantly reduced levels of ULK1, 
ULK2, or a double knock-down of ULK1 
and ULK2. The purpose of these knock 
down treatments was to observe and record 
both the metabolic effects of reduced 
autophagy, such as an increase or decrease 
in related metabolic factors, as well as to 
observe phenotypic differences in the mouse 
model. These phenotypic differences were 
observed as an increased body weight, 
increased insulin resistance, and decreased 
glucose sensitivity in mice bred to display 
deficiencies in the autophagy process. 
However, these knock down models only 
allowed a one-way view into the 
overarching metabolic process. In order to 
fully understand the overarching process 
governing the observed results, the effects of 
increased autophagy also needed to be 
observed. 
 Prior to the completion of this 
project, no simple factor was known to 
cause a reliable increase in autophagy 
activity without also having significant 
auxiliary effects on unrelated metabolic 
factors. As such, the current landscape for 
autophagy activators was not useful nor 
present for the purpose of experimentally 
increasing autophagic activity while also 
keeping secondary metabolic factors 
constant. It was also determined that a drug 
treatment—as opposed to genetic 
manipulation—would prove most useful in 
the scope of the overarching research goal. 
This was determined as countering the 
knock-down effects of gene editing and 
selection with the effects of a ULK1 agonist 
drug could lead to interesting results. If the 
effects of genetic knock down could be 
countered with the identified agonist, for a 
removal of the metabolic effects caused by 
autophagy deficiency, significant support 
would be added to the research goal of 
supporting that autophagy has a significant 
impact in cellular metabolism and the 
diabetes disease state. 
 
Methodology 
 After the cell samples were prepared, 
each set of samples were analyzed using a 
western blot analysis scheme. For all in vitro 
samples, the first step in this process was to 
extract all protein from the cell samples. 
This was conducted using RIPA buffer and a 
protease/phosphatase inhibitor lysis 
technique, in which the lysis buffer was 
added to each sample. The obtained solution 
was then vortexed and centrifuged, yielding 
a homogenized protein sample 
corresponding to each experimental 
condition. These protein samples were then 
analyzed using a microBCA analysis step, 
which yielded the total concentration of all 
protein in each sample. Using this 
information, stock samples were prepared 
for western blot analysis in which protein 
was diluted using a 4x sample buffer and 
water to yield protein samples with identical 
total concentrations. Thus, while the 
concentrations of individual proteins of 
interest would vary between the samples, 
variance due to differing overall protein 
concentrations was eliminated. 
 The next step of the western blot 
analysis scheme was to then resolve the 
protein samples according to molecular 
weight and image the samples. First, the 
protein samples were resolved on a running 
step, on which proteins are resolved along 
an electrophoresis gel as a voltage gradient 
separated the various proteins through the 
gel based on their molecular weights. Higher 
molecular weight proteins travelled less 
distance in the gel than did lower molecular 
weight proteins. A ladder of known protein 
sizes was also resolved on the gel as a 
reference. Depictions of the running tank 
setup, and the samples and ladder resolved 
on the gel, are provided below in figures 4 
and 5. 
 
Figure 4: Depiction of running gel setup 
with connected power supply.  
 
Figure 5: Depiction of protein ladder and 
samples resolved on running gel.  
 
After the running gel had concluded, 
the proteins were then transferred to a 
nitrocellulose membrane in the transfer step. 
This was accomplished by stacking the 
running gel on top of a nitrocellulose 
membrane and applying a voltage gradient 
across this ‘sandwich’. The voltage gradient 
caused the proteins contained within the gel 
to migrate and become bound into the 
nitrocellulose membrane. This transfer 
served to both affix the proteins into a stable 
position, as well as to expose portions of the 
proteins outside of the membrane for 
recognition using antibody selection. This 
transfer step was accomplished by either 
applying a 100 Volt gradient for only an 
hour, or by applying a 40 Volt gradient and 
allowing the transfer step to continue 
overnight. The transfer step was always 
conducted at 4°C to avoid degradation of 
data due to localized heating within 
nitrocellulose membrane. The results 
obtained using either technique are assumed 
to have provided identically reliable results, 
as no significant difference in effectiveness 
was observed while conducting the 
experimental protocol. 
 Following completion of the transfer 
step, the nitrocellulose membrane was 
divided into sections with only one protein 
of interest in each section. The proteins used 
as markers in this experiment were ULK1, 
FIP200, GAPDH, BNIP3, ATG13, P62, 
LC3B, AKT, and pAKT. At this point, the 
empty space of the nitrocellulose membrane 
was blocked using skim milk to prevent 
nonspecific associations during the antibody 
detection step. A primary antibody for each 
protein of interest was incubated on its 
respective membrane piece overnight. 
Following this incubation, a secondary 
antibody—with an attached fluorescent 
tag—specific to the animal type of each 
respective primary antibody was added to 
each membrane section. This allowed 
detection of concentration of each protein of 
interest in each cell sample provided, as the 
complex of secondary antibody bonded to 
primary antibody bonded to protein allowed 
the relative quantification of protein 
concentration. These concentrations were 
always compared to a control set of cell 
samples for each experimental repetition.  
 The concentration of protein was 
quantified using the relative amount of 
fluorescence emitted, through the use of the 
fluorescent tag on the secondary antibody, 
for each protein of interest. The fluorescence 
detected on the spatial region on the 
membrane corresponding to the protein and 
conditions of interest was recorded using 
autoradiography methods. The proteins 
bound on nitrocellulose membrane were 
incubated with an enhanced 
chemiluminescent substrate, which activated 
the fluorescent tag. At this point, through the 
use of a dark room to avoid film spoilage, 
X-ray film was exposed to the membranes 
for varying time periods. The fluorescent tag 
would be detected and recorded by the X-
ray film, with longer exposure times 
corresponding to a larger change on the X-
ray film. After development of the film, 
distinct bands would present on the X-ray 
film that correspond to the relative 
concentration of each protein of interest. 
Through the comparison to controls, the 
relative concentrations of the proteins of 
interest for each experimental condition 
could be quantified.   
 The initial experimental trials to 
screen forskolin as an autophagic inductor 
were conducted in vitro, varying the 
concentration of forskolin added as well as 
varying a starvation condition. Both the 
starvation and control conditions were 
treated with either no forskolin—as the 
control—and then with 1 micromolar or 10 
micromolar forskolin experimental 
condition. The non-starvation cells were 
incubated with 10% FBS (fetal bovine 
serum), while the starvation condition cells 
were incubated without serum. This set of 
conditions was repeated twice to validate the 
results of the first trial. 
 The second set of experimental 
conditions evaluated using a western blot 
analysis scheme was to remove the 
starvation condition, and now include a 
condition where the expression of ULK1 
was artificially knocked-down using siRNA. 
A control set was run along with this new 
experimental condition, incubating cells in 
either no forskolin, a 1 micromolar solution 
of forskolin, or a 10 micromolar solution of 
forskolin. The siRNA condition was 
repeated for both a control group—one in 
which the expression level of ULK1 was not 
knocked down—as well as for a group 
where siRNA was used to knock down the 
expression level of ULK1. For both the 
siRNA control and experimental group, cells 
were either treated with vehicle only—as a 
control—or were treated with a 10 
micromolar solution of forskolin. This 
experimental protocol was repeated two 
times, to validate the results obtained in the 
first experimental trial. 
 The third set of experimental 
conditions evaluated using a western blot 
analysis scheme was to expose the in vitro 
samples to insulin as well as to forskolin. 
For this experimental trial, both an siRNA 
control group and an siULK1 group were 
used. For each group, cells were either 
exposed to only vehicle (as a control group), 
to a solution containing 100nM forskolin for 
15 minutes, to a 10 micromolar 
concentration of forskolin, or were exposed 
to both insulin and forskolin treatments. For 
this experimental condition, the proteins 
pAKT, AKT total form, GAPDH, and 
ULK1 were measured. This experimental 
condition was only conducted once.  During 
all western blot experiments, if the 
possibility arose, replicates were created on 
the same membrane to test for reliability. 
These replicates were from the same cell 
sample and treatment day, and as such only 
prove to demonstrate that the results 
obtained for a given experiment were valid. 
They do not constitute an increase in overall 
sample size.  
 In addition to the maintenance of 
both cell culture colonies for in vitro testing 
and the use of western blot analysis, a series 
of mouse colonies were also maintained for 
the purposes of testing forskolin in an in 
vivo setting. Colonies of knock-down mice 
were bred and selected to either exhibit 
knock-down genotypes for ULK1, ULK2, or 
for ULK1/2. It was determined during the 
testing of the overarching hypothesis 
governing the involvement of ULK1 and 
ULK2 in diabetic symptom presentation that 
ULK2 did not have a profound impact, and 
as a result ULK2 mice were not prioritized 
during the breeding process. Starting in the 
fall of 2016, over the course of two years 
and over two hundred mice, the mice colony 
for ULK1 progressed from homozygous 
wild type mice, to heterozygous knock-
down mice, to finally displaying a 
homozygous knock-down genotype during 
the spring of 2018. Over the same two year 
period, ULK2 mice also displayed a general 
trend towards containing purely 
homozygous knock-down mice, as a 
hundred and fifty mice were genotyped and 
differentiated based on ULK2 expression 
level. It is expected that the ULK2 colony 
will contain purely homozygous knock-
down mice by the end of 2018. Finally, the 
ULK1/2 double-knockdown mice colony 
was started in the spring of 2017, with 
approximately 150 mice bred and genotyped 
prior to the termination of the project.  
 The purpose of breeding the mouse 
colonies mentioned was to both test the 
overarching experimental conditions not 
pertaining to this project’s specific 
hypothesis—e.g., the analysis of forskolin as 
a ULK1 agonist—as well as to develop an in 
vivo testing base for the forskolin 
treatments. While the effect of forskolin 
injection was not studied in the mouse 
model due to time constraints, the 
maintenance of the mouse colony is 
included within the methods as the mouse 
colony will likely be utilized in the future by 
other experimenters to characterize the in 
vivo response. Thus, while not directly used 
within this project, future experiments 
conducted to analyze the in vivo response to 
forskolin directly rely on the work 
conducted within this project. 
 Finally, the identification of the 
transcription levels of ULK1 and other 
factors of interest was identified using the 
creation of cDNA. This was accomplished 
through the extraction of RNA from cell 
culture, and subsequent creation of cDNA. 
RNA was extracted using a trypsin lysis 
buffer, with subsequent washes conducted 
using chloroform and ethanol. RNA was 
separated from other organic molecules 
using a centrifugation step, similar to how 
protein was extracted for western blot 
analysis. Following the extraction of RNA, 
concentration, purity, and contamination 
levels were identified using a NanoDrop 
machine, which utilizes Beer’s Law to 
interpolate concentration of nucleic acids 
based on a solution’s absorbance. Following 
confirmation that the samples had 
adequately low contamination and high 
purity levels, cDNA stocks were created 
from each cell RNA sample using a standard 
thermocycler protocol. The created cDNA 
was then utilized for further polymerase 
chain reactions, to amplify a select RNA 
transcript. In this manner, the expression 
level of select RNA transcripts inside a cell 
could be identified by resolving amplified 
cDNA samples on an agarose gel. In this 
manner, relative amounts of RNA in each 
cell sample could be compared, utilizing the 
principal that different molecular weight 
DNA strands would resolve to different 
lengths on the agarose gel. The location in 
the gel where bands of interests resolved to 
could be compared to a standard ladder as 
well as to literature to confirm that the bands 
of interest were indeed the metabolic factors 
of interest. In this manner, controls from cell 
samples could be compared to experimental 
cell conditions to determine if the ULK1 
agonist—or other added metabolic factors—
altered the occurrence level of autophagy in 
the cell sample. 
 
Results 
 The first western blot conducted on 
December 8th was used to evaluate the 
effects of forskolin on hepatic cells and 
yielded the following results. The loading 
scheme used is depicted in table 1. 
Table 1: Loading scheme of Western Blot 
conducted on December 8th.  
 
 
A: Expression levels of ULK1 for loading 
scheme detailed in table 1. 
 
B: Expression levels of LC3B and ATG13 
(with two replications of LC3B), for the 
loading scheme detailed in table 1. 
 
C: Expression levels of FIP200 for the 
loading scheme detailed in table 1. 
Figure 6 (A-C): Expression levels of select 
factors for loading scheme detailed in table 
1. 
 
Vehicle 1uM Forskolin 5uM Forskolin 10uM Forskolin Vehicle 1uM Forskolin 5uM Forskolin 10uM Forskolin
Serum Free (Starvation)10% FBS
The next western blot was conducted on 
January 25th, 2018, and served to confirm 
the expression levels of the secondary 
factors of interest measured in the first 
western blot. The loading scheme used is 
diagramed in table 2, with the following 
figures depicting protein expression levels. 
Table 2: Loading scheme for western blot 
conducted on January 25th.  
 
 
A: Expression levels of LC3B and Beclin1, 
with two replications of LC3B, for the 
loading scheme detailed in table 2. 
 
B: Expression levels of GAPDH for the 
loading scheme detailed in table 2. 
 
C: Expression levels of FIP200, with two 
replicates, for the loading scheme detailed in 
table 2. 
 
D: Expression levels of ATG13 for the 
loading scheme detailed in table 2. 
 
E: Expression levels of p62 for the loading 
scheme detailed in table 2. 
Figure 7 (A-E): Expression levels of select 
factors for loading scheme detailed in table 
2.  
 
The next western blot was conducted on 
February 8th, and served as a final 
confirmation of the conditions used in the 
prior two western blots. A starvation 
condition was again used, with forskolin 
added in varying amounts as according to 
the loading scheme detailed in table 2. The 
following results were obtained. 
 
A: Expression levels of p62 for the loading 
scheme detailed in table 2. 
  
B: Expression levels of LC3B and FIP200, 
with two replications of LC3B, for the 
loading scheme detailed in table 2. 
 
Vehicle 1uM Forskolin 10uM Forskolin Vehicle 1uM Forskolin 10uM Forskolin
10% FBS Serum Free (Starvation)
 
C: Expression levels of GAPDH for the 
loading scheme detailed in table 2. 
 
D: Expression levels of FIP200 for the 
loading scheme detailed in table 2. 
 
E: Expression levels Bnip3 for the loading 
scheme detailed in table 2.
 
F: Expression levels Beclin1 for the loading 
scheme detailed in table 2.
 
G: Expression levels of ATG13 for the 
loading scheme detailed in table 2. 
 
H: Expression levels of ULK1, with three 
replicates, for the loading scheme detailed in 
table 2. 
Figure 8 (A-H): Replicate expression levels 
of select factors for loading scheme detailed 
in table 2.  
 
 The third western blot conducted in 
this project concluded on February 15th. The 
purpose of this experiment trial was to both 
confirm the results obtained in prior western 
blots—except for those obtained using 
starvation conditions—as well as to 
introduce the new experimental condition of 
siRNA use. The loading scheme used is 
depicted below in table 3. 
Table 3: Loading scheme for western blot 
conducted on February 15th.  
 
 
A: Expression levels of ULK1, with three 
replicates, for the loading scheme detailed in 
table 3. 
Vehicle 1uM Forskolin 10uM Forskolin Vehicle 10uM Forskolin Vehicle 10uM Forskolin
Replicate Trial siCon siULK1
 
B: Expression levels of p62 for the loading 
scheme detailed in table 3.
 
C: Expression levels of LC3B, with two 
replicates, for the loading scheme detailed in 
table 3.
 
D: Expression levels of GAPDH, with two 
replicates, for the loading scheme detailed in 
table 3.
 
E: Expression levels of FIP200 for the 
loading scheme detailed in table 3.
 
F: Expression levels of Bnip3 for the 
loading scheme detailed in table 3.
 
G: Expression levels of Beclin1 for the 
loading scheme detailed in table 3.
 
H: Expression levels of ATG13 for the 
loading scheme detailed in table 3. 
Figure 9 (A-H): Expression levels of select 
factors for loading scheme detailed in table 
3.  
 
The fourth western blot conducted in 
this project concluded on March 1st. The 
purpose of this experiment trial was to 
confirm the results of the siRNA condition. 
Due to experimental error, only the 
expression levels for ULK were obtained. 
The loading scheme used is depicted below 
in table 4. 
Table 4: Loading scheme for western blot 




Figure 10: Expression levels of ULK1 for 
the loading scheme detailed in table 4. 
 
The fifth western blot conducted in 
this project concluded on March 29th. The 
purpose of this western blot was to 
investigate the effects insulin treatments 
would have, in addition to the effects of 
forskolin, when combined with the effects of 
siRNA. The loading scheme used is depicted 
below in table 5.  
Vehicle 10uM Forskolin Vehicle 10uM Forskolin Vehicle 1uM Forskolin 10uM Forskolin
Replicate TrialsiCon siULK1
Table 5: Loading scheme for the western 
blot conducted on March 29th. 
 
 
A: Expression levels of pAKT for the 
loading scheme detailed in table 5. 
 
B: Expression levels of GAPDH for the 
loading scheme detailed in table 5. 
 
C: Expression levels of AKT for the loading 
scheme detailed in table 5. 
 
Figure D: Expression levels of ULK1, with 
two replicates, for the loading scheme 
detailed in table 5. 
Figure 11 (A-D): Expression levels of select 
factors for loading scheme detailed in table 
5.  
 In addition to the western blot 
experiments, an analysis using RNA 
transcription levels was conducted. The 
expression levels of ULK1 and GAPDH 
mRNA were evaluated and are depicted 
below in figure 12, for a loading scheme 
detailed in table 6.  





A: Expression levels of GAPDH. 
 
 
B: Expression levels of ULK1. 
Figure 12: Measured mRNA levels, using a 
cDNA amplification technique, using the 
loading scheme detailed in table 6.  
 
Discussion 
Analysis of the results from the 
initial western blots—those conducted to 
screen for ULK1 indication—indicate that 
forskolin is not a direct activator of 
autophagy. The results from the first western 
blot display a clear increase in ULK1 
expression levels as a result of forskolin 
addition, in both non-starvation and 
starvation conditions. This result coincided 
with the increase in FIP200 levels with 
increasing concentrations of ULK1, as 
FIP200 complexes with ULK1. LC3B levels 
decreased markedly in starvation conditions, 
however there was no change in the non-
starvation condition. This result was 
inconsistent with the expectation of 
autophagy induction. Finally, while ATG13 
Vehicle Insulin Forskolin Insulin + Forskolin Vehicle Insulin Forskolin Insulin + Forskolin
siRNAsiCon
Vehicle Vehicle 1uM Forskolin 1uM Forskolin 10uM Forskolin 10uM Forskolin
levels also remained consistent across 
experimental conditions, which was 
inconsistent with forskolin acting as an 
autophagy agonist. The mixed results of this 
experiment led to further replicates being 
conducted to confirm the results obtained. 
The results obtained on January 25th 
yielded no significant aide to the hypothesis, 
as many of the results were inconsistent with 
forskolin acting as an autophagy inductor. 
FIP200 and ATG13 were observed to have 
no significant increase compared to control 
levels, a result inconsistent with autophagy 
induction. GAPDH was observed to 
decrease in starvation conditions, an effect 
opposite that of expectation. Also, GAPDH 
levels were observed to decrease, a result 
consistent if autophagy were inducted 
through a separate pathway than GAPDH, 
thus inhibiting GAPDH expression. LC3B 
expression was observed to have been 
invalidated due to the presence of a bubble 
present during the transfer step of the 
western blot, distorting the results such that 
they are unusable. The levels of p62 
remained consistent across the non-
starvation levels, indicating no build up due 
to autophagy deficiency. Finally, Beclin1 
levels were observed to have no distinct 
increase, inconsistent with forskolin acting 
as an autophagy inductor. Due to the 
inconsistency of these results, it was 
determined that additional western blots 
were needed to continue to investigate 
whether forskolin acted as an autophagy 
inductor. 
The following experiment served as 
an additional replication trial for the 
previous two western blot trials. The results 
of this experiment served to confirm that 
forskolin did not act as a direct autophagy 
agonist. While ULK1 levels were observed 
to greatly increase for increasing 
concentrations of forskolin, ATG13 levels 
were observed to remain relatively constant 
across experimental conditions. Finally, 
FIP200 levels remained consistent across 
trials, indicating that while forskolin 
increased the overall expression of ULK1, it 
did not drastically increase the formation of 
the autophagosome. GAPDH levels 
remained consistent across forskolin levels, 
consistent with expectations as forskolin 
was not expected to modulate the starvation-
induction process of autophagy. LC3B 
levels were inconsistent across replicates in 
the same western blot, and as such further 
replicates should be conducted to fully 
characterize the effect of forskolin on LC3B. 
Consistent with previous experiment trials, 
p62 levels remained consistent across 
experimental conditions. Finally, Bnip3 
levels were observed to significantly 
increase for increasing levels of forskolin, 
suggesting that forskolin may still play some 
role in autophagy induction. 
Further experimentation focused on 
the cellular response to forskolin in 
environments where ULK1 levels were 
artificially knocked-down due to the use of 
siRNA. This allowed for the identification 
of autophagy levels when the desired target 
of forskolin—ULK1—was removed. The 
results from the western blot conducted on 
February 15th continue to indicate that 
forskolin causes an increase in ULK1 levels, 
and the knock-down of ULK1 levels due to 
siRNA use was confirmed. The levels of p62 
were observed to remain constant across all 
trials, consistent with a lack of autophagy 
deficiency. The levels of LC3B were 
observed to have no significant difference 
across trials. GAPDH levels were observed 
to remain constant across forskolin levels 
and siRNA treatments, consistent with the 
hypothesis that forskolin does not modulate 
starvation-induced autophagy. FIP200 levels 
were observed to decrease for siULK1 
treatments, consistent with the expectation 
that knock-down of ULK1 would prevent 
the complex formation. Additionally, adding 
forskolin did not increase FIP200 in siULK1 
conditions, supporting the hypothesis that 
forskolin only acts as an agonist to ULK1. 
ATG13 levels were observed to remain 
constant across trials, consistent with 
previous experiment trials. Beclin1 levels 
were observed to not significantly change 
across trials, inconsistent with the 
hypothesis that forskolin acts as a autophagy 
agonist but consistent with previous 
experimental results. Beclin1 levels were 
also observed to not change in siULK1 
treatments, inconsistent with expectations 
and warranting further replications. Finally, 
Bnip3 levels were observed to decrease for 
increasing concentrations of forskolin, a 
result that is inconsistent with the hypothesis 
and with previous experimental results. This 
is likely due to Bnip3 being difficult to 
detect using the detection scheme used. 
Normal ECL solution was utilized for all 
other proteins of interest, however Bnip3 
consistently required the use of a super-
signal solution, which results in an increase 
in image distortion. As such, the results 
obtained are not reliable and should be 
replicated in future experimental trials prior 
to a definite conclusion being drawn on 
forskolin.  
While the majority of the results for 
the western blot experiment conducted on 
March 1st were lost—due to a failure in the 
transfer step—the results for ULK1 levels 
remained intact. These results remained 
consistent with previous experiment trials, 
whereby ULK1 levels increased for 
increasing forskolin levels and were 
observed to significantly decrease for 
siULK1 conditions. 
The final western blot conducted in 
the experimental plan served to explore the 
effects insulin treatment would have on 
autophagy induction. Insulin addition was 
expected to decrease the induction of 
autophagy, as the glucose level inside the 
cell would increase, causing the cell to be 
more metabolically active.  
The experimental results show that 
ULK1 levels increased in forskolin addition 
conditions, with higher expression levels in 
insulin treatments. This coincides with the 
paradigm that ULK1 is involved in the 
insulin signaling pathway. GAPDH levels 
remained constant across trials, consistent 
with expectations and previous experimental 
results. Finally, pAKT levels were observed 
to increase in insulin treatment conditions 
and in forskolin treatment conditions, 
relative to the control. Further replications 
should be conducted to fully characterize the 
effect forskolin has on the insulin signaling 
pathway. However, the phosphorylation of 
AKT in forskolin treatment conditions, 
coinciding with an increase in ULK1 levels, 
is consistent with the proposal that forskolin 
increases ULK1 expression, which then has 
a role in the insulin signaling pathway.  
 
Conclusion 
 The results obtained during this 
project are by no means complete nor 
satisfactory towards the definitive 
conclusion that forskolin acts as an 
autophagy inductor through the direct 
increase in ULK1 transcription. While the 
results of the experiments conducted suggest 
that forskolin is, indeed, a transcription 
agonist for ULK1, further research needs to 
be conducted to further support this 
hypothesis. In addition, the full 
characterization of autophagy related genes 
indicates that the increase in ULK1 was not 
matched by an equal increase in autophagy 
induction. Therefore, it is unlikely that 
forskolin acts in a direct manner to induce 
autophagy.  
 Due to time constraints, the 
experiments conducted in this experiment 
were limited to in vitro models only. 
However, further support could be obtained 
should a mouse model be utilized to 
characterize the autophagy response to 
forskolin, both in insulin-treatment 
conditions and in standard conditions. In 
addition, further research should be 
conducted into both the side effects of 
forskolin addition—namely, the effects on 
other autophagy pathways—and into the 
RNA transcription levels of the proteins of 
interest.  
 Finally, the analysis of mRNA levels 
was mostly inconclusive. While the levels of 
GAPDH remained constant, consistent with 
prior western blot results, the levels of 
ULK1 were invalidated due to a faulty 
control. Given that the second vehicle 
sample tested as having an equal 
concentration of ULK1 as the 10uM 
forskolin treatment condition, no significant 
conclusion can be taken from the 
experiment. However, the observed trend 
still shows an overall increase in ULK1 
expression for increasing concentrations of 
forskolin, and as such this experiment would 
benefit from replication to minimize the 
observed error in the control level of ULK1.  
Over the course of multiple experimental 
replicates, most of the inconsistencies 
between data were minimized and the 
cellular response to forskolin was 
characterized with reasonable confidence. 
Unfortunately, the cellular response did not 
indicate a direct induction of autophagy 
when ULK1 levels were increased. 
However, the role of forskolin and ULK1 in 
the insulin signaling pathway does hold 
promise as a line of investigation, and as 
such further experimentation should be done 
to fully characterize the autophagy response 
when both the insulin signaling pathway and 
forskolin levels are modulated.  
This project serves as only a pilot 
study for future research endeavors. Due to 
the lack of statistical analyses, varying cell 
lines, and lack of in vivo models, the results 
can not be extrapolated beyond the scope of 
the current project. However, the results are 
promising and suggest that should further 
research be conducted to characterize the 
cellular response to forskolin, a modulator 
of autophagy that has connections to the 
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